Indigenous Method and Safety of Mitomycin C in Refractory Corrosive Esophageal Strictures_JUniper Publishers








Authored by Neeraj Nagaich  


Abstract

Increasingly frequent dilation may become a self-defeating cycle in refractory stricture as recurrent trauma enhance, scar formation, and ultimately recurrence and potential worsening of the stricture. In twelve patients of caustic induced esophageal stricture, who failed to respond despite rigorous dilatation regimen for more than one year, a trial of topical mitomycin -C application to improve dilatation results was undertaken, considering the recently reported efficacy and safety of this agent. No data available on safety and efficacy of Mitomycin c in refractory strictures. Mitomycin c was applied for 2 to 3 minutes at the strictured oesophageal segment after dilation with wire guided SG dilator. Patient was kept NBM for 2-3 hour. After 4-6 sessions of Mitomycin-C treatment resolution of symptoms and significant improvement in dysphagia score and PDI was seen in all 12 patients. Mitomycin-C, topical application may be a useful strategy in refractory corrosive oesophageal strictures and salvage patients from surgery. This study suggests safety and efficacy of Mitomycin c in refractory strictures.
Keywords: Refractory Stricture; Mitomycin-c; periodic dilatation index (PDI)

Introduction

Caustic esophageal strictures still represent a challenge to endoscopist. Standard treatment is regular esophageal dilatation until the resolution of dysphagia. Caustic strictures require dilations more frequently for a positive clinical response [1]. Increasingly frequent dilation may become a self- defeating cycle in refractory stricture as recurrent trauma to the mucosa, enhance scar formation through enhanced fibroblast proliferation and collagen deposition, and ultimately recurrence and potential worsening of the stricture [2,3]. In many cases endoscopic dilatation fails and therefore esophageal replacement is eventually required. Non operative management of refractory stricture is limited. No data available on safety and efficacy of Mitomycin c in refractory strictures.

Materials and Methods

This hospital based observational descriptive study was done during april 2011- dec 2012 in Department of gastroenterology, SMS medical college, Jaipur to assess the efficacy of topical mitomycin-C in refractory caustic induced esophageal stricture. Twelve patients of refractory caustic esophageal strictures who reported in our department were enrolled as and when they met the inclusion criteria, last case was enrolled six months before Dec-2012. After obtaining informed consent, a trial of topical mitomycin-C application to improve dilatation results was undertaken, considering the recently reported efficacy and safety of this agent, in refractory stricture [4,5]. Baseline characteristic of all patients i.e age, sex, number of strictures duration of treatment dysphagia score ,periodic dilation index(PDI) etc were recorded from available records.

A cotton pledget held by endoscopic forceps was soaked in a 0.4-mg/mL solution of mitomycin-C and was then applied topically under direct vision, by front-loading the pledget in a standard cap used for band ligation of varices attached to the end of the endoscope, to prevent the mitomycin-C from touching normal mucosa. This was applied for 2 to 3 minutes at the strictured oesophageal segment after dilation with wire guided SG dilator. After the application patient was kept nill by mouth for 2-3 hour. All patients were observed for local and systemic side effect during 24 hours of admission after each local application of Mitomycin c and on discharge patients were instructed to report back if they have any complaint thereafter. No local or systemic side effects resulting from mitomycin-C application was observed. Topical application was repeated at 4 week interval along with scheduled dilatation sessions every week. The ability to swallow was expressed as a dysphagia score. The scoring system was modified from that reported by Mellow and Pinkas; a score of 0 denoted the ability to eat a normal diet; 1, the ability to eat some solid food; 2, the ability to eat semisolid only; 3, the ability to swallow liquids only; and 4, complete dysphagia [6].

A periodic dilation index (number of dilations required per month) before and after MC application was calculated. All these parameters were re-recorded at four or six months after topical application of mitomycin-C. The periodic dilatation index (PDI) was calculated for the last 12 week duration in all patients.

The end point of successful outcome of the treatment was considered when once 14 size dilator could be passed easily and dysphagia score improved by one grade from baseline. End point data was collected in 6 patient at 4 month, 5 patients at 5 months and in 2 patients at 6 months.

Results

The average no. of (times) dilatation, the study subjects underwent before MC application was 58.6 (SD 8.4) with a mean duration of dilatation 14.7 (SD is 2.3). The average no of application of topical mitomycin c among cases was 4.75 (SD 0.75). The average Dysphagia score before application of topical mitomycin was 2.5 (SD 0.52), which reduced to 0.91 (SD 0.66) after application. This depicts a statistically significant reduction in dysphagia score after MC. (P<0.0001/paired t test).
The average PDI before MC was 3.99 (SD 0.36) that was reduced to 2.58 (SD 0.32) after MC. Interpretation-There was a statistically significant reduction in average PDI score after MC (P <0.0001/paired t test). After 4-6 sessions of Mitomycin-C treatment, significant clinical improvement on follow-up endoscopy (>14 fr. Dilator passed easily), and resolution of symptoms and marked improvement in dysphagia score was seen in all 12 patients. The PDI calculated for 12 weeks following MC application also decreased significantly in all the patients.

Discussion

Mitomycin c, an anthracycline derived alkylating agent from streptomyces caespitous, has antineoplastic and anti proliferative properties. It inhibits DNA and protein synthesis, has been shown to inhibit fibroblast proliferation and collagen synthesis and may prevent stricture recurrence by interfering with normal wound healing processes [2,4]. It's anti proliferative properties on fibroblasts have been shown in vivo and in vitro[7].

Favorable clinical responses to the topical application of Mitomycin-C reducing scar formation have recently been reported in the treatment of surgical wound healing and adhesions [8]. Mitomycin C should be applied precisely only to the stricture mucosa. Various techniques have been used to topically deliver Mitomycin-C to the anastomotic stricture [5]. Mucosal application of Mitomycin-C has been shown to be an effective and safe treatment of recalcitrant esophageal stricture [5]. Concentrations of the Mitomycin-C described in the various anatomical regions vary however the concentration of 0.4mg/mL is most commonly used one. This anti fibroblastic approach may be used in preference to steroid application locally or systemically, in which the results have not been rewarding because these agents approach the problem from an anti-inflammatory angle rather than the more appropriate anti scARGHing post dilation mode.

Majority of prior studies [4,5] of mitomycin c application were in pediatric age patient, in this study all the patients were above 16 year age thus suggesting efficacy of topical Mitomycin c in adult patients also. The use of Mitomycin-C seems to improve the outcome by making stricture supple early and large size dilators can be passed easily and early. The optimal duration of Mitomycin c application has yet to be determined. Further studies may validate this weapon for recalcitrant strictures.

Conclusion

Post dilatation application of topical Mitomycin-C resulted in major success in endoscopic and symptomatic criteria, and it may be a useful strategy in corrosive esophageal strictures refractory to repeated endoscopic dilatation. This study suggests safety and efficacy of Mitomycin c in refractory strictures.





 

Comments

Post a Comment

Popular posts from this blog

Milk Curd Syndrome: A Forgotten Entity_Juniper Publishers

Image
ADVANCED RESEARCH IN GASTROENTEROLOGY & HEPATOLOGY JUNIPER PUBLISHERS   Authored by Kashish Khanna Abstract A full term neonatal baby girl presented with a lumbosacral meningomyelocele and underwent successful excision and repair. In the postoperative period, she developed abdominal distension, bilious vomiting and did not pass stools. Conservative management for ileus/intestinal obstruction failed. The abdominal exploration revealed milk curd syndrome (MCS) as a cause of intestinal obstruction. This article highlights the varied presentation of MCS and salient features to differentiate it from other causes of neonatal intestinal obstruction. Keywords: Neonatal intestinal obstruction; Milk curd syndrome; Inspissated milk syndrome; Milk plug syndrome Abbreviations: MCS: Milk Curd Syndrome; SBE: Small Bowel Obstruction; NEC: Necrotising Enterocolitis; MMC: Meningomyelocele; TCA: Total Colonic Aganglionosis ...
Read more

A Modified Sequential Regimen of Helicobacterpylori Treatment Enforced by Bacillus clausii and Zinc Carnosine Complex Yields High Eradication Rates_Juniper Publishers

Image
  ADVANCED RESEARCH IN GASTROENTEROLOGY & HEPATOLOGY JUNIPER PUBLISHERS   Authored by Dajani AI      Abstract Introduction: Over the past decade a worldwide trend of decline in the cure rates of Helicobacter pylori is observed. Current eradication rates achieved by the standard triple therapy are below 70%. Sequential therapy had provided a potential alternative that would compensate for the unmet performance of triple therapy. Despite its superiority to triple therapy, the excellent results reported initially were not reproduced by other investigators work. Adding adjuvant agents was also found to improve further the success rate of eradication. Probiotics emerged as a useful adjunct in treatment and prophylaxis of Helicobacter pylori infection. The nutritional supplement Zinc carnosine complex is another adjuvant which is believed to add value to the treatment. Patients and method: an open label randomized observational clinical study ...
Read more

Updating on Neuroendocrine Tumors New Clinical Evidence in the Search of the Ideal Treatment Sequence_Juniper Publishers

Image
ADVANCED RESEARCH IN GASTROENTEROLOGY & HEPATOLOGY JUNIPER PUBLISHERS Authored by Juan Manuel O'Connor   Introduction Neuroendocrine tumors (NETs) represent a heterogeneous clinical entity with an increasing incidence as shown by the different registers available. As opposed to other solid tumors, NETs represent a challenge, not only from the diagnostic standpoint but also in terms of treatment strategies. According to the data published by our Working group, ARGENTUM GROUP [ 1 ], with more than 600 patients assessed, roughly 60% of the cases present with metastatic disease from the onset. The reason why the incidence of advanced disease is high since early onset may be due to a bias, for most of the physicians in our Group are oncologists. Moreover, about 20% of the patients included present poorly differentiated NETs, a heterogeneous subgroup, with high risk and poor outcome according to the different series reported. G grading...
Read more